It’s overtaking older GLP 1 meds in clinical use

Trends show tirzepatide is already the most prescribed GLP-1 class drug in the US

Its dual GLP-1 GIP action gives a clinical edge in weight loss

More physicians are choosing it first line for diabetes obesity

Other GLP 1 drugs still hold market share especially in weight loss

Oral GLP 1 options could diversify defaults

New competitors may prevent one default from monopolizing

Its superior weight loss in trials boosts its adoption

Clinicians may still prefer semaglutide in some patients

If access expands it may become the go to choice

Overall it’s strongly trending toward default but isn’t universally there yet

New molecules could shift the landscape again

Real-world use reflects strong growth for tirzepatide